Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($)	3 Months Ended													6 Months Ended		12 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2017	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Disaggregation of Revenue [Line Items]
Collaboration revenue														$ 53,044,000	$ 50,034,000	$ 234,603,000	$ 91,280,000
Milestone revenue recognition														Cash is generally received within 30 days of milestone achievement.
GSK \| PD-1 (Jemperli/Dostarlimab)
Disaggregation of Revenue [Line Items]
Collaboration revenue														$ 0		125,000,000	40,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Disaggregation of Revenue [Line Items]
Collaboration revenue													$ 1,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| IND clearance from the FDA
Disaggregation of Revenue [Line Items]
Collaboration revenue												$ 4,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Phase 2 clinical trial initiation
Disaggregation of Revenue [Line Items]
Collaboration revenue											$ 3,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Phase 3 clinical trial initiation - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue										$ 5,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Phase 3 clinical trial initiation - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue									$ 5,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Filing of the first BLA - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue								$ 10,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Filing of the first MAA - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue								$ 5,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Filing of the first BLA - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue							$ 10,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| First BLA approval - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue						$ 20,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| First MAA approval - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue						$ 10,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| First BLA approval - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue					$ 20,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Filing of the first MAA - second indication
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														5,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| First MAA approval - second indication
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														10,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| First commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue				$ 15,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Second commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue			$ 25,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Third commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue		$ 50,000,000														125,000,000	$ 40,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Fourth commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue	$ 75,000,000															75,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Milestones recognized through December 31, 2025
Disaggregation of Revenue [Line Items]
Collaboration revenue														258,000,000
GSK \| PD-1 (Jemperli/Dostarlimab) \| Milestones that may be recognized in the future
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														15,000,000
Sagard \| PD-1 (Jemperli/Dostarlimab) \| Third commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue																$ 50,000,000
Vanda \| Milestones recognized through December 31, 2025
Disaggregation of Revenue [Line Items]
Collaboration revenue														0
Vanda \| Milestones that may be recognized in the future
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														35,000,000
Vanda \| FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														5,000,000
Vanda \| Regulatory approval for marketing of the first licensed product in the EU
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														5,000,000
Vanda \| Commercial sales first exceed $100.0 million
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														$ 25,000,000